Targeted therapy of lung cancer-data from Asia / 中国癌症杂志

ABSTRACT

3 months. Female gender, adenocarcinoma history, non-smoking history, good PS and the presence of multiple lung metastases are associated with improved responsiveness to Gefitinib. Reflecting the results of previous clinical trials, the reports indicate that Gefitinib is generally well tolerated by Asian patients. The incidence of interstitial lung disease appears to be higher in Japanese than non-Japanese patients, although the reason for this is not clear. Recent findings regarding Erlotinib and other targeted therapy among Asian patients are discussed.